secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001437749-23-012576
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q1 net income $1.4M vs loss; NERLYNX revenue $46.8M (+15% YoY)
---------------------------------------------------------------------------

- GAAP net income $1.4M ($0.03/diluted share) vs net loss of $3.4M in Q1 2022.
- Non-GAAP adjusted net income $4.2M ($0.09/share) vs adjusted net loss of $0.3M.
- Q1 product revenue (NERLYNX) $46.8M, up from $40.7M YoY; royalty revenue $6.0M.
- Cash and marketable securities $71.2M at March 31, 2023 vs $81.1M at Dec 31, 2022.
- Guidance: FY 2023 net product revenue $205-210M; net income $20-24M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/pbyi20230502_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-012576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer